跳至主要内容
临床试验/NCT00140725
NCT00140725已完成3 期

A Randomised Trial of Lamivudine Plus Interferon Versus Lamivudine for the Treatment of HBeAg Positive Chronic Hepatitis B Virus (HBV)

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2000年4月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
160
试验地点
1
主要终点
Proportion of patients with HBeAg seroconversion to anti-HBe

研究概览

简要总结

This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Untreated chronic hepatitis B patients with evidence of HBV replication as documented by serum HNV-DNA positive within 3 months prior to entry and serum HBeAg positive at screening.
  • Documented presence of abnormal alanine aminotransferase (ALT) (1.3 - 5X upper limit normal (ULN)) within 1 month prior to entry and signs of compensated liver disease.

排除标准

  • Patients with any cause for liver disease other than chronic hepatitis B and evidence or history of decompensated liver disease.

结局指标

主要结局

Proportion of patients with HBeAg seroconversion to anti-HBe

次要结局

  • Normalization of alanine aminotransferase (ALT)
  • Undetectable HBV DNA
  • Histologic improvement
  • Tyrosine, methionine, aspartate, aspartate (YMDD) mutants among the viremic relapsers at the end of therapy and safety of treatment

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验